Aplastic Anemia (AA)- Market Is Expected to Grow with Upcoming Therapies

New Delhi, India -- (SBWIRE) -- 03/22/2018 -- Aplastic Anemia (AA) is a rare and non-cancerous disease that occurs when a person's bone marrow no longer creates enough blood cells. It is believed that aplastic anemia is an autoimmune disorder because the new cells seem to be attacked by the current cells. This limits the amount of new cells that can be created. It is a potential life-threatening hematopoietic stem cell (HSC) disorder with an estimated incidence of 2–3 per million per year. Studies have shown that contact with certain toxins such as benzene and radiation, to viruses such as hepatitis, and to some medications can cause this disease. Aplastic Anemia affects men at somewhat higher rates that it affects women.

According to the latest report of DelveInsight, "Aplastic Anemia (AA)- Market Insights, Epidemiology and Market Forecast - 2027", In the United States and other developed countries the disease prevalence is so low that too few cases occur to make an epidemiological study in a single city logistically feasible. As per Aplastic Anemia & MDS International Foundation, between 600 and 900 people are diagnosed with aplastic anemia each year in the United States. Treatment is divided into supportive and specific, the latter constitutes, immunosuppressive treatment. The therapeutic market is mainly driven by the use of medications such as Immunosuppressant's like Cyclosporine (Gengraf, Neoral) and Corticosteroids, such as methylprednisolone (Medrol, Solu-Medrol) for treating Aplastic Anemia.

As per National Organization for rare disease (NORD), the incidence of aplastic anemia in Europe and Israel is two new cases among 1 million people per year while in Asia, incidence rate is two or three times greater. The therapies under development are focused on novel approaches to treat/improve the disease condition. Emerging therapies such as Romiplostim (Kyowa Hakko Kirin Co., Ltd), BL-8040 (BioLineRx Ltd) and others, are expected to change the treatment landscape of Aplastic Anemia in upcoming years. With the launch of upcoming therapies Aplastic Anemia market is expected to grow during the period of 2018-2027.

The latest report has covered detailed disease background and overview. Epidemiology details and patient population covering 7MM is also provided to better understand the disease distribution pattern. Treatment algorithm along with treatment guidelines are also covered to understand the present treatment practices. Detailed profiling of the marketed as well as pipeline drugs is also provided to understand the product potential and identifying promising therapies. Country-wise market analysis of Aplastic Anemia is also provided covering the 7MM to identify the major markets in the Respective domain. Report has also covered all the possible market drivers and barriers to understand the market and plan the strategies accordingly and remain ahead of the market competitors.

Reasons to buy:
-The report will help in developing business strategies by understanding trends shaping and driving the Aplastic Anemia market.
-To understand the future market competition in the Aplastic Anemia market and Insight reviews of the key market drivers and barriers.
-Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
-In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:
-Kyowa Hakko Kirin Co., Ltd
-BioLineRx Ltd
-Amgen Pharmaceuticals
-Novartis Pharmaceuticals

Request for Sample pages:
Aplastic Anemia - Market Insight, Epidemiology and Market Forecast - 2027: https://www.delveinsight.com/report-store/aplastic-anemia-market-insight-epidemiology-and-market-forecast

Aplastic Anemia - Epidemiology Forecast to 2025: https://www.delveinsight.com/report-store/aplastic-anemia-epidemiology-forecast

Aplastic Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017: https://www.delveinsight.com/report-store/aplastic-anemia-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape

Aplastic Anemia - Pipeline Insight, 2017: https://www.delveinsight.com/report-store/aplastic-anemia-pipeline-insight

Table of Contents:

1. Report Introduction

2. Aplastic Anemia Market Overview at a Glance

2.1. Global Market Size of Aplastic Anemia in 2017

2.2. Global Market Size of Aplastic Anemia in 2027

3. Disease Background and Overview: Aplastic Anemia

3.1. Introduction

3.2. Causes

3.3. Pathophysiology

3.4. Symptoms

3.5. Risk Factor

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Aplastic Anemia Geography Wise Incident Cases

4.1.1. 7MMIncident Cases of Aplastic Anemia in 2017

4.1.2. 7MMIncident Cases of Aplastic Anemia in 2027

4.2. United States

4.2.1. Assumptions and Caveats

4.2.2. Incident Cases of Aplastic Anemia

4.2.3. Sex-Specific Incident Cases of Aplastic Anemia

4.3. EU-5

4.4. Germany

4.4.1. Assumptions and Caveats

4.4.2. Incident Cases of Aplastic Anemia

4.4.3. Sex-SpecificIncident Cases of Aplastic Anemia

4.5. Italy

4.5.1. Assumptions and Caveats

4.5.2. Incident Cases of Aplastic Anemia

4.5.3. Sex-SpecificIncident Cases of Aplastic Anemia

4.6. Spain

4.6.1. Assumptions and Caveats

4.6.2. Incident Cases of Aplastic Anemia

4.6.3. Sex-SpecificIncident Cases of Aplastic Anemia

4.7. France

4.7.1. Assumptions and Caveats

4.7.2. Incident Cases of Aplastic Anemia

4.7.3. Sex-SpecificIncident Cases of Aplastic Anemia

4.8. United Kingdom

4.8.1. Assumptions and Caveats

4.8.2. Incident Cases of Aplastic Anemia

4.8.3. Sex-SpecificIncident Cases of Aplastic Anemia

4.9. Japan

4.9.1. Assumptions and Caveats

4.9.2. Incident Cases of Aplastic Anemia

4.9.3. Sex-SpecificIncident Cases of Aplastic Anemia

5. Treatment Practices

5.1. Treatment Algorithm

5.2. Treatment Guidelines

5.2.1. European Group for Blood and Marrow Transplantation: Recommendations

5.2.2. US

5.2.3. Japan

6. Marketed Products

6.1. Promacta (eltrombopag): Novartis Pharmaceuticals

6.1.1. Drug Description

6.1.2. Mechanism of Action

6.1.3. Regulatory Milestones

6.1.4. Advantages & Disadvantages

6.1.5. Safety and Efficacy

6.1.6. Product Profile

6.2. Neupogen (filgrastim): Amgen Pharmaceuticals

6.2.1. Drug Description

6.2.2. Mechanism of Action

6.2.3. Regulatory Milestones

6.2.4. Advantages & Disadvantages

6.2.5. Safety and Efficacy

6.2.6. Product Profile

To be continued in the report…

7. Key Emerging Therapies

7.1. Key Cross Competition

7.2. Romiplostim:Kyowa Hakko Kirin Co., Ltd

7.2.1. Regulatory Milestones

7.2.2. Clinical Development

7.2.3. Product Profile

7.2.4. Clinical Pipeline Activity

7.2.5. Ongoing Trials Information

7.2.6. Clinical Trial by Phase

7.3. BL-8040:BioLineRx Ltd

7.3.1. Regulatory Milestones

7.3.2. Clinical Development

7.3.3. Product Profile

7.3.4. Clinical Pipeline Activity

7.3.5. Ongoing Trials Information

7.3.6. Clinical Trial by Phase

To be continued in report…

8. Aplastic Anemia Market Size

8.1. Key Findings

8.2. Total 7MM Aplastic Anemia Market Analysis

8.2.1. Overview of Total Aplastic Anemia Market (2016-2027)

8.2.2. 7MM Aplastic Anemia : Country-Wise Market Analysis

8.2.3. United States Market Size

8.2.3.1. Market Analysis

8.2.3.2. Emerging therapies analysis: Impact on the market

8.2.4. Germany Market Size

8.2.4.1. Market Analysis

8.2.4.2. Emerging therapies analysis: Impact on the market

8.2.5. France Market Size

8.2.5.1. Market Analysis

8.2.5.2. Emerging therapies analysis: Impact on the market

8.2.6. United Kingdom Market Size

8.2.6.1. Market Analysis

8.2.6.2. Emerging therapies analysis: Impact on the market

8.2.7. Spain Market Size

8.2.7.1. Market Analysis

8.2.7.2. Emerging therapies analysis: Impact on the market

8.2.8. Italy Market Size

8.2.8.1. Market Analysis

8.2.8.2. Emerging therapies analysis: Impact on the market

8.2.9. Japan Market Size

8.2.9.1. Market Analysis

8.2.9.2. Emerging therapies analysis: Impact on the market

9. Report Methodology

9.1. Sources Used

10. DelveInsight Capabilities

11. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.

For more information on this press release visit: http://www.sbwire.com/press-releases/aplastic-anemia-aa-market-is-expected-to-grow-with-upcoming-therapies-953150.htm